Journal
THERAPEUTIC ADVANCES IN CARDIOVASCULAR DISEASE
Volume 11, Issue 3, Pages 81-90Publisher
SAGE PUBLICATIONS LTD
DOI: 10.1177/1753944715622130
Keywords
edoxaban; atrial fibrillation; Novel oral anticoagulants; factor xa inhibitor; non-vitamin K oral anticoagulants
Categories
Ask authors/readers for more resources
Edoxaban, a direct factor Xa inhibitor, was extensively studied in the prevention and treatment of venous thromboembolism and in patients with nonvalvular atrial fibrillation (AF). The aim of this review is to focus specifically on the efficacy and safety profile of edoxaban in patients with AF from preclinical development through the phase III trial that led to regulatory approval.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available
Share Paper
